As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

We ranked the 10 best commercials from the 2025 Super Bowl and found them online so you can judge them for yourself.

The UK Chancellor’s messaging at Davos recalled former Taoiseach Enda Kenny’s efforts to extol the recovery of the Irish ...

Welcome to the Wall Street Week newsletter, bringing you stories of capitalism about things you need to know, but even more ...

The Genesis Prize Foundation’s Stan Polovets highlights the impact of Thessaloniki's Holocaust Museum and global efforts ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Pfizer CEO Albert Bourla told investors he dined with RFK Jr, a vaccine skeptic and nominee to head HHS. They discussed ...

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...